Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
|
|
INVO Bioscience, Inc. (IVOB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"REVENUE LOAN AND SECURITY AGREEMENT THIS REVENUE LOAN AND SECURITY AGREEMENT is made as of September 29, 2023 , by and among: STEVEN SHUM , INVO BIOSCIENCE INC., a Nevada corporation, 5582 Broadcast Court Sarasota, FL 34240 , the parties listed under the heading “Guarantors” on the signature pages attached hereto , and DECATHLON ALPHA V, L.P., a Delaware limited partnership, 1441 West Ute Boulevard, Suite 240 Park City, UT 84098 . BACKGROUND Company wishes to borrow from Lender and Lender wishes to lend to Company an amount up to the Revenue Loan Amount on the terms and conditions of this Agreement. In connection with and as a material inducement to Lender to lend the Revenue Loan Amount to Company, Company desires to make certain representations and warranties to Lender. AGREEMENT The par...",
"SUBORDINATION AGREEMENT THIS SUBORDINATION AGREEMENT is made as of September 29, 2023, among: INVO BIOSCIENCE INC., a Nevada corporation, 5582 Broadcast Court Sarasota, FL 34240 ; DECATHLON, ALPHA V L.P., a Delaware limited partnership, 1441 West Ute Boulevard, Suite 240 Park City, UT 84098 ; and CEDAR ADVANCE LLC 5401 Collins Avenue, CU-9A Miami Beach, FL 33140 . BACKGROUND The Senior Creditor intends to make certain credit available to Debtor pursuant to a Revenue Loan and Security Agreement of even date herewith , between Debtor and the Senior Creditor. The Subordinating Creditor has made certain credit available to Debtor pursuant to a Standard Merchant Cash Advance Agreement dated as of August 31, 2023 , between the Debtor and Subordinating Creditor. AGREEMENT The parties agree as fol...",
"Decathlon Alpha V, L.P." |
|
| 10/03/2023 |
8-K
| Other Events Interactive Data |
| 10/02/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/29/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
SC 13G
| INTRACOASTAL CAPITAL, LLC reports a 7.1% stake in INVO Bioscience, Inc. |
| 08/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...|
Docs:
|
"PHYSICIAN EMPLOYMENT AGREEMENT",
"Agreement”) is effective as of August 10, 2023 , by and between Wood Violet Fertility LLC, a Delaware limited liability company , Wisconsin Fertility and Reproductive Surgery Associates, S.C., a Wisconsin corporation (“Provider",
"Term; Termination.",
"EMPLOYMENT AGREEMENT",
"SECURITY AGREEMENT",
"PHYSICIAN LIAISON AGREEMENT",
"DIRECTED EQUITY TRANSFER AGREEMENT",
"INVO Closes Acquisition of Wisconsin Fertility Institute",
"INVO BIOSCIENCE, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On March 16, 2023, INVO Bioscience Inc., a Nevada corporation , through Wood Violet Fertility LLC, a Delaware limited liability company and wholly owned subsidiary of INVO Centers LLC, a Delaware company wholly owned by INVO, entered into binding purchase agreements to acquire Wisconsin Fertility Institute for a combined purchase price of $10 million . The purchase price is payable in four installments of $2.5 million each, payable at closing and on each of the subsequent three anniversaries of closing. The sellers have the option to take all or a portion of the final three installments in shares of INVO common stock valued at $125.00, $181.80, and $285.80, for the second, third, and final installments, respe..." |
|
| 08/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...|
Docs:
|
"Attention: Mr. Steven Shum, Chief Executive Officer",
"Schedule of Fees as Agent",
"ASSIGNMENT FORM",
"NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED , AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.",
"ARTICLE I. DEFINITIONS 1.1 Definitions . In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1: “ Acquiring Person ” shall have the meaning ascribed to such term in Section 4.5. “ Action ” shall have the meaning ascribed to such term in Section 3.1 . “ Affiliate ” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. “ Agent’ s Counsel ” means Loeb & Loeb LLP, with offices located at 345 Park Avenue, New York, New York 10154. “ Board of Directors ” means the board of directors of the Company. “ Business ...",
"INVO Bioscience Announces Pricing of $4.5 Million Public Offering",
"INVO Bioscience Announces Closing of $4.5 Million Public Offering" |
|
| 08/07/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/02/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 07/31/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/27/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ... |
| 07/24/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Page 1 of 4",
"DEMAND PROMISSORY NOTE",
"WARRANT INVO BIOSCIENCE, INC. Warrant Shares: 150,000 Initial Issuance Date: July 10, 2023 Initial Exercise Date: July 10, 2023 THIS WARRANT certifies that, for value received, JAG MULTI INVESTMENTS LLC or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 10, 2023 and on or prior to the close of business on the five year anniversary of the Initial Issuance Date set forth above but not thereafter, to subscribe for and purchase from INVO Bioscience, Inc., a Nevada corporation , up to 150,000 shares of Common Stock having an expiration date on the Termination Date. The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Secti...",
"Closing Agreement This Closing Agreement is effective as of July 7, 2023, and entered into by and among Wood Violet Fertility LLC, a Delaware limited liability company and Wisconsin Fertility and Reproductive Surgery Associates, S.C., a Wisconsin professional service corporation d/b/a Wisconsin Fertility Institute , The Elizabeth Pritts Revocable Living Trust , and Dr. Elizabeth Pritts, an individual and sole trustee of Seller . W I T N E S S E T H: WHEREAS, the Parties entered into an Asset Purchase Agreement dated March 16, 2023 ; WHEREAS, the defined terms in this Agreement are, unless otherwise specified herein, as they are defined in the Asset Purchase Agreement; and WHEREAS, the parties desire to complete the Closing on or before July 31, 2023. NOW, THEREFORE, in consideration of the...",
"Closing Agreement" |
|
| 07/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/07/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 07/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 07/03/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 06/30/2023 |
8-K/A
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"INVO BIOSCIENCE, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On March 16, 2023, INVO Bioscience Inc., a Nevada corporation , through Wood Violet Fertility LLC, a Delaware limited liability company and wholly owned subsidiary of INVO Centers LLC, a Delaware company wholly-owned by INVO, entered into binding purchase agreements to acquire Wisconsin Fertility Institute for a combined purchase price of $10 million . The purchase price is payable in four installments of $2.5 million each, payable at closing and on each of the subsequent three anniversaries of closing. The sellers have the option to take all or a portion of the final three installments in shares of INVO common stock valued at $6.25, $9.09, and $14.29, for the second, third, and final installments, respective..." |
|
| 05/22/2023 |
4
| Szot Matthew K (Director) has filed a Form 4 on INVO Bioscience, Inc.|
Txns:
| Granted 85,000 options to buy
@ $0.368, valued at
$31.3k
|
|
| 05/22/2023 |
4
| Shum Steve (CEO) has filed a Form 4 on INVO Bioscience, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.368, valued at
$36.8k
|
|
| 05/22/2023 |
4
| Ryan Barbara (Director) has filed a Form 4 on INVO Bioscience, Inc.|
Txns:
| Granted 85,000 options to buy
@ $0.368, valued at
$31.3k
|
|
| 05/22/2023 |
4
| Messina Rebecca (Director) has filed a Form 4 on INVO Bioscience, Inc.|
Txns:
| Granted 85,000 options to buy
@ $0.362, valued at
$30.8k
|
|
| 05/22/2023 |
4
| Goren Andrea (CFO) has filed a Form 4 on INVO Bioscience, Inc.|
Txns:
| Granted 81,000 options to buy
@ $0.368, valued at
$29.8k
|
|
| 05/22/2023 |
4
| DAVIS TRENT D (Director) has filed a Form 4 on INVO Bioscience, Inc.|
Txns:
| Granted 85,000 options to buy
@ $0.368, valued at
$31.3k
|
|
| 05/22/2023 |
4
| Campbell Michael Jos. (COO) has filed a Form 4 on INVO Bioscience, Inc.|
Txns:
| Granted 83,000 options to buy
@ $0.368, valued at
$30.5k
|
|
|
|
|